BIDMC Investigator Contributes To FDA Approval of New and Better Way To Test Osteoporosis Treatments
BIDMC investigator Mary Bouxsein helped secure FDA approval of bone density imaging as a faster endpoint for osteoporosis ...
Khaberni - An international research team has made a scientific discovery that could change the future of osteoporosis ...
Morning Overview on MSN
Discovery could one day reverse osteoporosis, scientists say
For decades, osteoporosis has meant a slow, one way slide toward fragile bones and fracture risk, managed but rarely truly ...
Boston-based Beth Israel Deaconess Medical Center played a role in a new FDA decision that allows bone mineral density, measured through noninvasive imaging, to serve as a qualified endpoint in ...
Millions of osteoporosis patients worldwide are set to benefit from a major international breakthrough, which will transform ...
16d
FNIH Announces FDA Qualification of First Surrogate Endpoint for Use in Osteoporosis Clinical Trials
The Foundation for the National Institutes of Health (FNIH) announces that the Food and Drug Administration (FDA) has qualified the treatment-related change in hip bone mineral density (BMD) as a ...
Osteoporosis is characterized by an imbalance in bone renewal, where bone loss outpaces bone replacement, leading to weakened, brittle bones. Various factors contribute to osteoporosis, including ...
On Monday, the Food and Drug Administration issued a new draft guidance that requires drug manufacturers to conduct long-term nonclinical bone quality studies for osteoporosis treatments. The agency ...
A research team from the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine at the University of ...
NEW ORLEANS — New Endocrine Society guidelines on the pharmacologic treatment of osteoporosis in postmenopausal women aim to encourage clinicians to boost rates of screening and treatment for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback